Epidemiology of Crohn???s Disease, Journal of Clinical Gastroenterology, vol.8, issue.2, pp.160-165, 1986. ,
DOI : 10.1097/00004836-198604000-00011
Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD), Digestive and Liver Disease, vol.45, issue.2, pp.89-94, 2013. ,
DOI : 10.1016/j.dld.2012.09.005
URL : https://hal.archives-ouvertes.fr/tel-00820631
Role of genetic and environmental factors in British twins with inflammatory bowel disease, Inflammatory Bowel Diseases, vol.18, issue.4 ,
DOI : 10.1002/ibd.21747
Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease ,
The relationship between inflammatory bowel disease and socioeconomic variables, The American Journal of Gastroenterology, vol.119, issue.7 ,
DOI : 10.1016/0021-9681(71)90087-7
El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature, Am. J ,
Passive Smoking and Inflammatory Bowel Disease: A Meta-Analysis, The American Journal of Gastroenterology, vol.29, issue.9, pp.2382-2393, 2008. ,
DOI : 10.1111/j.1572-0241.2008.01999.x
Acute Gastroenteritis Is Followed by an Increased Risk of Inflammatory Bowel Disease, Gastroenterology, vol.130, issue.6, pp.1588-1594, 2006. ,
DOI : 10.1053/j.gastro.2006.02.004
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, Gut, vol.55, issue.suppl_1, pp.1-15, 2006. ,
DOI : 10.1136/gut.2005.081950a
Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort, The American Journal of Gastroenterology, vol.107, issue.1, pp.110-119, 2011. ,
DOI : 10.1016/j.crohns.2007.10.006
The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study, Gastroenterology, vol.129, issue.3 ,
DOI : 10.1053/j.gastro.2005.06.021
Initial experience with wireless capsule enteroscopyin the diagnosis and the management of inflammatory bowel disease ,
Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.10, issue.2, pp.1097-1104, 2006. ,
DOI : 10.1080/00855910310001430
High frequency of early colorectal cancer in inflammatory bowel disease, Gut, vol.57, issue.9, pp.1246-1251, 2008. ,
Review article: appropriate use of corticosteroids in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.312, issue.Suppl. 1, pp.313-329, 2007. ,
DOI : 10.1111/j.1365-2036.2007.03379.x
Clinical, biological, and endoscopic picture of attacks of Crohn's disease, Gastroenterology, vol.98, issue.4, pp.811-818, 1990. ,
DOI : 10.1016/0016-5085(90)90002-I
Azathioprine and 6-Mercaptopurine in Crohn Disease, Annals of Internal Medicine, vol.123, issue.2, pp.132-142, 1995. ,
DOI : 10.7326/0003-4819-123-2-199507150-00009
Azathioprine for maintaining remission of Crohn's disease, Cochrane Database Syst Rev, issue.2, p.67, 2000. ,
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, The Lancet, vol.347, issue.8996, pp.215-219, 1996. ,
DOI : 10.1016/S0140-6736(96)90402-X
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease, The Lancet, vol.343, issue.8908, pp.1249-1252, 1994. ,
DOI : 10.1016/S0140-6736(94)92150-4
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, The Lancet, vol.374, issue.9701, pp.1617-1642, 2009. ,
DOI : 10.1016/S0140-6736(09)61302-7
URL : https://hal.archives-ouvertes.fr/hal-00466312
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.664-53, 2008. ,
DOI : 10.1016/j.cgh.2008.03.014
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997. ,
DOI : 10.1056/NEJM199710093371502
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002. ,
DOI : 10.1016/S0140-6736(02)08512-4
CLASSIC-I Study the Efficacy of Adalimumab, Gastroenterology, vol.130, issue.6 ,
DOI : 10.1053/j.gastro.2006.03.050
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1, pp.52-65, 2007. ,
DOI : 10.1053/j.gastro.2006.11.041
Adalimumab sustains steroid-free remission after 3???years of therapy for Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.103, issue.Suppl. 2, pp.306-317, 2011. ,
DOI : 10.1111/j.1365-2036.2011.04717.x
Effect of adalimumab on clinical laboratory parameters in patients with Crohn??s disease: Results from the CHARM trial, Inflammatory Bowel Diseases, vol.18, issue.5, pp.818-825, 2012. ,
DOI : 10.1002/ibd.21836
W1089 Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease, Gastroenterology, vol.136, issue.5, pp.1308-1327, 2009. ,
DOI : 10.1016/S0016-5085(09)63003-1
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases, Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1863-1872, 2009. ,
DOI : 10.1136/ard.2008.102103
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, vol.58, issue.4, pp.492-500, 2009. ,
DOI : 10.1136/gut.2008.155812
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review, The American Journal of Gastroenterology, vol.104, issue.4 ,
DOI : 10.1038/ajg.2008.38
Adalimumab for maintenance treatement of Crohn's disease : results of the CLASSIC II trial ,
GAIN for Loss: Adalimumab for Infliximab-Refractory Crohn Disease, Annals of Internal Medicine, vol.146, issue.12, pp.888-90, 2007. ,
DOI : 10.7326/0003-4819-146-12-200706190-00011
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.52, issue.10, pp.3279-3289, 2005. ,
DOI : 10.1002/art.21306
Human anti-tumornecrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial ,
Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study, Gut, vol.54, pp.81-82, 2005. ,
Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis, Ann Rheum Dis, vol.65, pp.181-182, 2006. ,
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.65, issue.7, pp.889-894, 2006. ,
DOI : 10.1136/ard.2005.043166
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial, Gastroenterology, vol.142, issue.5, pp.1102-1113, 2012. ,
DOI : 10.1053/j.gastro.2012.01.035
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease, Gastroenterology, vol.138, issue.2, pp.463-471, 2010. ,
DOI : 10.1053/j.gastro.2009.09.056
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease, Gastrointestinal Endoscopy, vol.63, issue.3, pp.433-475, 2006. ,
DOI : 10.1016/j.gie.2005.08.011
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn??s disease, Inflammatory Bowel Diseases, vol.15, issue.9, pp.1295-301, 2009. ,
DOI : 10.1002/ibd.20927
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.63, issue.9, pp.1122-1128, 2008. ,
DOI : 10.1111/j.1365-2036.2008.03828.x
Les taux sériques d'adalimumab sont associés à une rémission clinique et à une cicatrisation ,
Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases, Inflammatory Bowel Diseases, vol.19, issue.7, p.2013 ,
DOI : 10.1097/MIB.0b013e31828132cb